Histone Deacetylase 3 Inhibitors for Treating Demyelinating Diseases
HDAC3 inhibitors enhance myelin repair in white matter injury and demyelinating diseases
Treatment with Histone Deacetylase 3 (HDAC3) Inhibitors can promote myelination in the white matter during development. HDAC3 inhibitors can also enhance re-myelination and functional nerve recovery in the central and peripheral nerve systems (CNS and PNS) in animal models of multiple sclerosis. Targeting HDAC3 with these inhibitors also rejuvenates the age-related decline in functional recovery after nerve injury.
- Inhibiting histone deacetylase 3 may be used to treat demyelinating diseases.
- Histone deacetylase 3 inhibitors repair white matter damage and nerve regeneration after injury.
The most common demyelinating disease is Multiple Sclerosis (MS). More than 2.3 million people worldwide are affected by MS. Other myelination related neural disorders include Alzheimer’s disease, Parkinson’s disease, Huntington disease, and amyotrophic lateral sclerosis (ALS).
Qing (Richard) Lu, PhD., Division of Experimental Hematology and Cancer Biology